We have found an excellent partner for this deal in Hanover which is a publicly-traded real estate investment trust or REIT. They have strong mortgage reporting and surveillance systems and an excellent reputation in assisting government agencies in dealing with mortgage-related assets. Each of these strengths can help expand financing’s mortgage servicing capabilities as a stand-alone company but this transaction not only marks a momentous step in our strategy to transform Walter Industries into a pure-play natural resources company, but it also preserves the significant value in the mortgage portfolio for our shareholders.
One of the requirements for being a REIT is that the business cannot have undistributed earnings and profits. At the time of the spin-off JWH Holding Company will have some accumulated earnings and profits. The taxable distribution will eliminate this historical earnings and profits position through the taxable distribution. The distribution will be in the form of cash which can be used to pay taxes and stock of JWH Holding Company. The amounts of these distributions will be disclosed in future filings.
The new company which will be called Walter Investment Management Corporation will be led by Mark O’Brien who will serve as Chairman and CEO and Charles Cauthen who will serve as President and Chief Operating Officer. Mark O’Brien and Walter Industries Chairman Mike Tokarz will also serve on Walter Investment Management’s Board of Directors.
While a few closing conditions must be met before the transaction can be completed, such as receiving the private letter ruling from the IRS on certain tax issues, we have a relatively clear runway to close this transaction in early 2009.
The homebuilding business will be separated from JWH Holding Company prior to the merger and will not be part of this transaction. Although market conditions are not favorable, we continue to pursue the separation of this business and we expect to complete the process by year end.
In closing I want to congratulate Hanover on this transaction, thank our law firm Simpson Thacher, our investment banker Moelis & Company, and particularly [Joe Troy] who has led this project for us internally.
Recent HCM News
- HUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board Committee • GlobeNewswire Inc. • 05/08/2024 08:30:00 AM
- HUTCHMED Announces Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer Received by Takeda • GlobeNewswire Inc. • 04/26/2024 12:30:00 PM
- HUTCHMED Highlights Data to be Presented at AACR Congress 2024 • GlobeNewswire Inc. • 04/05/2024 08:30:00 AM
- HUTCHMED and Innovent Jointly Announce NDA Acceptance in China for Fruquintinib Combination with Sintilimab for the Treatment of Advanced Endometrial Cancer with Priority Review Status • GlobeNewswire Inc. • 04/02/2024 04:30:00 AM
- HUTCHMED Announces Savolitinib sNDA Accepted in China for Treatment-Naïve or Previously Treated Patients with Locally Advanced or Metastatic MET Exon 14 NSCLC • GlobeNewswire Inc. • 03/28/2024 12:00:00 AM
- HUTCHMED Initiates Registration Stage of the ESLIM-02 Phase II/III Trial of Sovleplenib for Warm Antibody Autoimmune Hemolytic Anemia in China • GlobeNewswire Inc. • 03/22/2024 12:00:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 03/05/2024 11:04:49 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 02/28/2024 11:47:15 AM
- Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/28/2024 11:40:32 AM
- HUTCHMED Reports 2023 Full Year Results and Provides Business Updates • GlobeNewswire Inc. • 02/28/2024 11:30:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 02/07/2024 11:43:27 AM
- HUTCHMED Highlights Presentation of Phase III Data on Fruquintinib in Second-Line Gastric Cancer at ASCO Plenary Series Session • GlobeNewswire Inc. • 02/07/2024 12:00:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 02/02/2024 11:15:00 AM
- HUTCHMED Announces that Inmagene Exercises Option to License Two Drug Candidates as Part of Strategic Partnership • GlobeNewswire Inc. • 02/02/2024 08:30:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 02/01/2024 11:06:10 AM
- HUTCHMED to Announce 2023 Final Results • GlobeNewswire Inc. • 02/01/2024 08:30:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 01/30/2024 11:17:32 AM
- HUTCHMED Receives ELUNATE® (fruquintinib) Marketing Approval in Hong Kong for Treatment of Metastatic Colorectal Cancer • GlobeNewswire Inc. • 01/30/2024 04:53:49 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 01/11/2024 11:02:53 AM
- HUTCHMED Announces NDA Acceptance in China for Sovleplenib for the Treatment of Primary Immune Thrombocytopenia with Priority Review Status • GlobeNewswire Inc. • 01/11/2024 12:00:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 12/29/2023 11:04:17 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 12/21/2023 11:14:15 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 12/13/2023 11:04:28 AM
- HUTCHMED Announces Continued Inclusion of ELUNATE® (fruquintinib) and SULANDA® (surufatinib) in the National Reimbursement Drug List in China at Current Terms • GlobeNewswire Inc. • 12/13/2023 04:30:00 AM
- HUTCHMED Announces that it has Completed Enrollment of a Phase II/III Trial of Fruquintinib in Combination with Sintilimab for Advanced Renal Cell Carcinoma in China • GlobeNewswire Inc. • 12/13/2023 12:00:00 AM
Avant Technologies Equipping AI-Managed Data Center with High Performance Computing Systems • AVAI • May 10, 2024 8:00 AM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM